Eperzan

RSS
Withdrawn

This medicine's authorisation has been withdrawn

albiglutide
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 29 October 2018, the European Commission withdrew the marketing authorisation for Eperzan (albiglutide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, GlaxoSmithKline Trading Services Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Eperzan was granted marketing authorisation in the EU on 21 March 2014 for the treatment of type 2 diabetes mellitus. 

The European Public Assessment Report (EPAR) for Eperzan is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Eperzan : EPAR - Summary for the public

Reference Number: EMA/57956/2014

English (EN) (562.4 KB - PDF)

First published: Last updated:
View

български (BG) (624.69 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

español (ES) (542.87 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

čeština (CS) (607.9 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

dansk (DA) (541.22 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Deutsch (DE) (544.32 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

eesti keel (ET) (540.43 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

ελληνικά (EL) (630.45 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

français (FR) (547.85 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

hrvatski (HR) (562.04 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

italiano (IT) (540.11 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

latviešu valoda (LV) (622.24 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

lietuvių kalba (LT) (565.35 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

magyar (HU) (595.19 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Malti (MT) (608.19 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Nederlands (NL) (541.07 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

polski (PL) (605.32 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

português (PT) (542.53 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

română (RO) (565.97 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenčina (SK) (606.51 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenščina (SL) (598.09 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Suomi (FI) (540.84 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

svenska (SV) (540.92 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Product information

Eperzan : EPAR - Product Information

English (EN) (1.3 MB - PDF)

First published: Last updated:
View

български (BG) (3.78 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

español (ES) (1.31 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

čeština (CS) (2.61 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

dansk (DA) (1.28 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Deutsch (DE) (2.91 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

eesti keel (ET) (1.28 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

ελληνικά (EL) (3.79 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

français (FR) (1.85 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

hrvatski (HR) (2.06 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

italiano (IT) (2.35 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

lietuvių kalba (LT) (2.5 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

magyar (HU) (2.8 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Malti (MT) (3.61 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Nederlands (NL) (1.74 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

norsk (NO) (1.9 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

polski (PL) (3.46 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

português (PT) (2.22 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

română (RO) (1.49 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenčina (SK) (2.84 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenščina (SL) (2.84 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Suomi (FI) (1.7 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

svenska (SV) (1.9 MB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View
Latest procedure affecting product information: II/0031
14/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Eperzan : EPAR - All Authorised presentations

English (EN) (464.95 KB - PDF)

First published: Last updated:
View

български (BG) (530.35 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

español (ES) (464.99 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

čeština (CS) (512.08 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

dansk (DA) (461.05 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Deutsch (DE) (479.46 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

eesti keel (ET) (473.97 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

ελληνικά (EL) (515.98 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

français (FR) (465.85 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

hrvatski (HR) (480.51 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

íslenska (IS) (545.36 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

italiano (IT) (556.13 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

latviešu valoda (LV) (511.54 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

lietuvių kalba (LT) (508.44 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

magyar (HU) (504.72 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Malti (MT) (511.91 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Nederlands (NL) (475.83 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

norsk (NO) (476.21 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

polski (PL) (522.9 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

português (PT) (473.83 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

română (RO) (511.84 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenčina (SK) (511.2 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

slovenščina (SL) (496.05 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Suomi (FI) (470.96 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

svenska (SV) (473.85 KB - PDF)

First published: 10/04/2014Last updated: 20/02/2019
View

Product details

Name of medicine
Eperzan
Active substance
Albiglutide
International non-proprietary name (INN) or common name
albiglutide
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BJ04

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:

Monotherapy

When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.

Add-on combination therapy

In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).

Authorisation details

EMA product number
EMEA/H/C/002735
Marketing authorisation holder
GlaxoSmithKline Trading Services Limited

12 Riverwalk
Citywest Business Campus
Dublin 24
D24 YK11
Ireland

Opinion adopted
22/01/2014
Marketing authorisation issued
20/03/2014
Withdrawal of marketing authorisation
29/10/2018
Revision
8

Assessment history

Eperzan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (656.63 KB - PDF)

First published: Last updated:
View

Eperzan : EPAR - Public assessment report

AdoptedReference Number: EMA/CHMP/705417/2013

English (EN) (4 MB - PDF)

First published: Last updated:
View

CHMP summary of positive opinion for Eperzan

AdoptedReference Number: EMA/CHMP/20616/2014

English (EN) (523.8 KB - PDF)

First published: Last updated:
View
This page was last updated on

Share this page

Back to top